Outer membrane vesicle as well as preparation method and application thereof

The intestinal bacteria of blood-sucking insects were cultured by serum induction method and OMV was collected, which solved the problems of low OMV yield and complex purification, and obtained high-efficiency, low toxicity and strong targeting OMV, which was suitable for drug delivery vehicles.

CN119060869APending Publication Date: 2024-12-03CAS CENT FOR EXCELLENCE IN MOLECULAR PLANT SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310637413.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently prepare outer membrane vesicles (OMVs). It has low yield, complex purification process and is difficult to completely remove residual bacterial allergens and toxic proteins. It is also not efficient to target eukaryotic cells, which limits OMV as a Application of drug delivery vehicles.

Method used

Serum induction method was used to cultivate intestinal bacteria from blood-sucking insects, and OMV was collected by filtration and centrifugation, avoiding the use of detergent and ultrafiltration concentration steps, and OMV with low LPS content and close to eukaryotic lipids were prepared.

Benefits of technology

It significantly improves the yield and purification efficiency of OMV, reduces toxicity and immunogenicity in vivo, enhances the targeting ability of OMV to eukaryotic cells, simplifies the preparation process, and reduces costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004268519990000181
    Figure BDA0004268519990000181
  • Figure HDA0004268520000000011
    Figure HDA0004268520000000011
  • Figure HDA0004268520000000012
    Figure HDA0004268520000000012
Patent Text Reader

Abstract

The invention provides a method for preparing an outer membrane vesicle (OMV), and further provides the outer membrane vesicle (OMV) prepared by the method, a composition of the OMV and application of the OMV in preparation of drugs for preventing diseases (such as preparing vaccines) and treating diseases (such as liver-stage plasmodium and malaria related to dormant species of the liver-stage plasmodium).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and more specifically, to a preparation method of outer membrane vesicles, a pharmaceutical composition and use thereof. Background Art

[0002] Extracellular vesicles (EVs) are secretory vesicles produced by cells based on a phospholipid bilayer. Different cells produce EVs in different ways and processes. Some bacteria, especially Gram-negative bacteria, can produce outer membrane vesicles (OMVs) in the form of outer membrane blistering.

[0003] OMV is a substance secreted by bacteria into the external environment. It has a diameter of 50-300nm and presents a double-membrane vesicle structure. OMV mainly contains components of the bacterial outer membrane such as phospholipids, outer membrane proteins, and lipopolysaccharides. It may also contain a small amount of components in the periplasm, inner membrane, and even the cytoplasm. The composition of OMV varies. Even if the OMV is produced by the same bacteria, the composition will change with the changes in the environment or stimulation of the bacteria. Under different stimulation conditions, the protein content in the vesicles is significantly different. For many pathogenic bacteria, from the perspective of having certain biologically active molecules such as adhesins, toxins, DNA, and quorum sensing molecules, OMVs carrying these molecules are of great significance to the pathogenicity and virulence of bacteria. From the research on various pathogenic bacteria, it can be found that they will produce vesicles at the site of infection. For example, they have been found in the cerebrospinal fluid and blood of patients with chronic Helicobacter pylori ulcers and meningitis caused by Neisseria meningitides. OMVs produced by pathogenic bacteria can also be found in host tissue cells infected by bacteria, indicating that vesicles have the ability to adapt to different environments and long-distance transport. Pathogenic bacteria often produce more OMVs than non-pathogenic bacteria. For example, the OMV content in the supernatant of enterotoxigenic Escherichia coli (E. coli) is ten times higher than that of non-pathogenic E. coli. In E. coli, Vibrio cholerae and Brucella melitensis, OMVs are most likely to form at the end of the logarithmic phase of bacterial growth.

[0004] Bacterial OMVs are usually induced under different stress conditions. Factors in the bacterial environment, such as iron ions, temperature, antibiotics, and reactive oxygen species, may affect the production of OMVs. For example, the production of OMVs in Escherichia coli increases under culture conditions without iron ions. The Gram-negative conditional pathogen Serratia rapa can produce a large number of vesicles at 22°C or 30°C, but the OMV production is extremely low at 37°C. Ciprofloxacin, meropenem, fosfomycin, and polymyxin all increase the production of OMVs in Escherichia coli. In addition, in Pseudomonas aeruginosa, after phage infection causes bacterial lysis, the ruptured membrane fragments will bend and renature to form vesicles. Although many environmental factors that affect OMV production have been discovered, the specific environmental components and the regulatory pathways by which bacteria sense these stimuli to upregulate or downregulate OMV production are still largely unclear.

[0005] OMV contains a variety of substances such as outer membrane proteins, lipopolysaccharides and nucleic acids. Due to its unique structure and rich antigenic components, OMV is often immunogenic. Since bacterial OMV is produced in the bacterial outer membrane, it inevitably carries bacterial toxic proteins, bacterial immunogenic lipopolysaccharides and secondary metabolites. For example, bacterial LPS (Lipopolysaccharides) is a strong allergen. Since LPS is essential for maintaining the structural integrity and physiological functions of bacterial membranes, complete knockout is impossible, and using detergents to treat OMVs to reduce LPS content cannot completely eliminate it, and it may also bring in detergents that are difficult to remove. Bacterial immunogens and toxic molecules, including LPS, are always difficult to remove, which limits the application of OMV as a carrier for anti-tumor drugs.

[0006] Another problem in the development of bacterial OMVs as drug delivery carriers is that the delivery efficiency of targeted eukaryotic cells is not as good as that of exosomes derived from eukaryotic cells. The lipid and protein components of some bacterial OMVs are highly similar to those of bacteria, and are quite different from those of eukaryotic cells. For example, most bacteria, including Escherichia coli, generally do not contain or contain less phosphatidylcholine (PC) and cholesterol (Cholesterol) anabolic pathways, while the plasma membrane of eukaryotic cells is rich in lipid rafts composed of PC and sterols such as cholesterol. Lipid similarity and lipidraft-mediated attachment-phagocytosis are the main pathways for vesicles such as exosomes to enter target cells. The difference between the lipid group of OMVs and target cells determines that the targeting of OMVs is not as good as that of exosomes derived from eukaryotic cells themselves.

[0007] Efficient acquisition of OMVs is the key to the development and utilization of this type of vesicle material. In order to facilitate the distinction of the sources of bacterial OMV preparation, Matthias et al. proposed a rough classification in 2017, proposing that bacterial-derived OMVs be mainly divided into spontaneously produced OMVs (sOMV, spontaneously released OMVs), OMVs obtained by stimulating bacterial cultures with various detergents (dOMV, Detergent extracted OMVs), and OMVs produced by stimulating bacterial cultures with non-detergent methods such as EDTA (eOMV). Since the absolute amount of spontaneously produced sOMVs from bacteria is relatively low, if sOMVs need to be prepared for application purposes, a large amount of fermentation culture is required, and they are concentrated and prepared from a large amount of bacterial culture supernatant. The preparation process is cumbersome and the yield is extremely low. In order to obtain more OMVs, detergents (dOMV) or non-detergent methods such as EDTA (eOMV) are often used to stimulate bacteria to obtain more OMVs. Compared with spontaneously generated OMVs, OMVs obtained by using detergents and other methods have the advantages of relatively low LPS content and promoted production, and are widely used in OMV vaccine development. However, these treatment processes often cause bacterial lysis and death and the release of secondary metabolites, DNA, proteins and other contents. Subsequently, DNA enzyme degradation is required to remove DNA impurities, and a variety of methods such as dialysis and column chromatography are combined to remove reagents such as detergents and impurities released by bacterial lysis, making the purification of OMV more complicated, cumbersome and costly. More importantly, these treatment steps inevitably affect the original biological activity of OMVs, especially the introduction of detergents, which may destroy the structure and properties of the OMV phospholipid bilayer and affect the activity of OMV loaded proteins, and it is difficult to completely remove them. In addition, although induced, the original yield of OMVs obtained by current technology in the fermentation stock solution is still generally low, and it is necessary to first perform a high-cost, long-time pre-concentration treatment. The commonly used salting-out concentration is easy to cause damage to the performance of OMVs and their loaded substances, and the membrane permeation concentration is expensive and not conducive to the removal of impurities.

[0008] The current production of bacterial OMVs is still relatively low, and it is always difficult to completely remove the residual bacterial allergens, toxic proteins, and by-products. In addition, the differences between bacterial OMVs and eukaryotic target cells in lipidome and proteome, and the fusion delivery efficiency with eukaryotic target cells is not as good as that of exosomes, have limited the current application of OMVs. The ultimate application of OMVs as drug delivery carriers requires effective breakthroughs in three aspects: improving OMV performance to reduce in vivo toxicity and immunogenicity, improving OMV targeting efficiency of eukaryotic cells, and improving OMV production and purification processes. Summary of the invention

[0009] The purpose of the present invention is to provide a preparation method of outer membrane vesicles, a composition thereof, a pharmaceutical composition and uses thereof.

[0010] In a first aspect of the present invention, a method for preparing outer membrane vesicles (OMV) is provided, comprising the following steps: (i) culturing intestinal bacteria derived from blood-sucking insects with a culture medium so that the bacteria release vesicles into the culture medium; and (ii) collecting the vesicles in the culture medium.

[0011] In one or more embodiments, the preparation method includes the step of inducing with a serum-containing substance; preferably, the serum-containing substance includes (but is not limited to): serum, plasma (whole blood), serum extract or serum substitute; preferably, the serum-containing substance is derived from mice, rats, humans, cattle, pigs, rabbits, sheep, and horses.

[0012] In one or more embodiments, the intestinal bacteria derived from blood-sucking insects include intestinal bacteria derived from Anopheles or Aedes.

[0013] In one or more embodiments, the enteric bacteria comprises Serratia.

[0014] In one or more embodiments, the intestinal bacteria include: Serratia ureilytica, Serratia marcescens, Serratia rubidaea, Serratia liquefaciens, Serratia plymuthica, Serratia ficaria, Serratia grimesii, Serratia fonticola, etc.

[0015] In one or more embodiments, the intestinal bacteria is Su_YN1, which is a strain with the deposit number CGMCC No.18971.

[0016] In one or more embodiments, the serum is bovine serum, which includes but is not limited to fetal bovine serum, newborn bovine serum, calf serum, and adult bovine serum; preferably, the serum is fetal bovine serum (FBS).

[0017] In one or more embodiments, the preparation method includes one or more of the following AG:

[0018] A. The culture temperature of the culture medium for culturing bacteria in step (i) is 15-33°C, preferably 18-32°C, more preferably 20-30°C (such as 22, 24, 26, 28°C);

[0019] B. The bacterial inoculation ratio in step (i) is seed solution: culture solution = 1:100, wherein the bacterial OD value of the seed solution is 1.0 OD to 3.0 OD, preferably 2.0 OD to 3.0 OD;

[0020] C. The culturing time of the bacteria in the culture medium in step (i) is 10 to 80 hours, preferably 12 to 60 hours, more preferably 15 to 48 hours (such as 18 to 24 hours, 20 to 24 hours, 21 to 24 hours, etc.);

[0021] D. The concentration of the serum is 3-20%, preferably 5-15%, more preferably 8-12%;

[0022] E. The method for collecting vesicles is to collect vesicles by filtration, centrifugation, or salting out; preferably, the filtration is performed using a filter, and / or the centrifugation is performed at 4°C low temperature; more preferably, the filtration is performed using a 0.2 μm filter; and / or the centrifugation is performed by ultracentrifugation with a centrifugal force of 10000g-25000g, and most preferably, the centrifugal force is 15000g.

[0023] In one or more embodiments, the preparation method does not include a pre-concentration step, preferably does not include a step of using ultrafiltration concentration or detergent precipitation concentration, and more preferably the detergent is trichloroacetic acid (TCA).

[0024] In one or more embodiments, the preparation method does not require dialysis or gradient purification.

[0025] In one or more embodiments, the preparation method further comprises the step of detecting and / or identifying lipid components by lipidome cluster analysis.

[0026] In one or more embodiments, the preparation method further includes a quantitative step, preferably the quantitative step is a quantitative detection by a BCA quantitative method based on total protein, and / or a Kdo quantitative method based on LPS content, and / or a quantitative method based on total lipid content.

[0027] In one or more embodiments, the preparation method further comprises the step of performing intuitive particle analysis using an NTA particle analyzer.

[0028] In a second aspect of the present invention, an isolated outer membrane vesicle (OMV) is provided, characterized in that it is prepared by the preparation method of the present invention.

[0029] In one or more embodiments, the outer membrane vesicle has a feature selected from the group consisting of:

[0030] The particles are uniform, with an average particle size of 100-150nm;

[0031] A lipid composition having eukaryotic properties; preferably, the lipids include (but are not limited to): phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, glycerophospholipids; preferably, the lipids are not mainly glycerophospholipids (content less than 10%) and LPS lipopolysaccharide (content less than 1%);

[0032] It has a protein composition derived from serum (lipoprotein and iron-binding protein, etc.) and intestinal bacteria derived from blood-sucking insects (proteins derived from the outer membrane such as Autotransporter);

[0033] It has a low LPS to lipopolysaccharide ratio; preferably, according to the Kdo method, the LPS amount is lower than 0.5 μg / 100 μg OMV, and more preferably lower than 0.4 μg / 100 μg OMV.

[0034] In the third aspect of the present invention, a composition is provided, which comprises the outer membrane vesicles of the present invention; preferably, the composition does not contain any living bacteria and / or intact bacteria.

[0035] In the fourth aspect of the present invention, a pharmaceutical composition is provided, comprising: the isolated outer membrane vesicle (OMV) described in the present invention; a therapeutic agent and / or a diagnostic agent integrated or loaded into the outer membrane vesicle; and a pharmaceutically acceptable carrier or excipient.

[0036] In one or more embodiments, the therapeutic agent comprises: anti-tumor drugs, anti-infective agents, anti-allergic agents, antianemic drugs, angiogenesis inhibitors, beta-adrenergic blockers, calcium channel antagonists, antihypertensive drugs, antidepressants, anticonvulsants, antibacterial drugs, antifungal drugs, antiviral drugs, antirheumatic drugs, antiparasitic drugs, antimalarial drugs, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, antidiabetic drugs, antiepileptic drugs, antihemorrhagic drugs, antihyperosmolar drugs, antiglaucoma drugs, immunomodulatory cytokines, sedatives, chemokines, vitamins, toxins, anesthetics, imaging agents and combinations thereof;

[0037] Preferably, the therapeutic agent is an antimalarial drug for treating hepatic stage Plasmodium and its hypnozoites, in particular an antimalarial drug for treating parasitemia of hepatic stage Plasmodium and its hypnozoites;

[0038] More preferably, the antimalarial drugs include artemisinin antimalarial drugs and aminoquinoline antimalarial drugs;

[0039] Most preferably, the artemisinin antimalarial drug includes artemisinin, artesunate, artemether, dihydroartemisinin or arteether, and the aminoquinoline antimalarial drug includes chloroquine, chloroquine phosphate, piperaquine, primaquine or primaquine phosphate; preferably, the antimalarial drug is primaquine;

[0040] and / or,

[0041] The diagnostic agent includes: an imaging agent, an immunomodulator, an antigen, an adjuvant, a cytokine, a chemokine, an anticancer agent, an anti-infective agent, a nucleic acid, an antibody or a fragment thereof, and a fusion protein; preferably, the diagnostic agent is an agent for diagnosing malaria associated with hepatic stage Plasmodium and its hypnozoites; more preferably, the diagnostic agent is an agent for diagnosing parasitemia associated with hepatic stage Plasmodium and its hypnozoites.

[0042] In a fifth aspect of the present invention, a complex is provided, characterized in that the complex comprises the isolated outer membrane vesicle (OMV) of the present invention and a lipolytic enzyme;

[0043] Preferably, the lipolytic enzyme is AmLip, or fragments, derivatives and analogs thereof,

[0044] More preferably, the AmLip comprises a protein having an amino acid sequence as shown in SEQ ID NO: 2; or a derivative protein having an amino acid sequence having more than 90% sequence identity with SEQ ID NO: 2 and having the function of the protein shown in SEQ ID NO: 2.

[0045] In the sixth aspect of the present invention, there is provided the use of the isolated outer membrane vesicles (OMV) of the present invention, the composition of the present invention, the pharmaceutical composition of the present invention or the complex of the present invention in the preparation of a medicament for preventing or treating a disease; preferably, the medicament for preventing a disease is a vaccine.

[0046] In one or more embodiments, the disease comprises tumor, infection, allergy, anemia, hypertension, depression, convulsion, bacterial infection, fungal infection, viral infection, rheumatism, parasites, malaria, immune system disease, nervous system disease, diabetes, epilepsy, bleeding, hyperosmosis, glaucoma, sedation, toxin, anesthesia.

[0047] In one or more embodiments, the disease is malaria, in particular malaria associated with Plasmodium and its hypnozoites.

[0048] In one or more embodiments, the disease is malaria associated with hepatic stage Plasmodium and its hypnozoites, in particular parasitemia associated with hepatic stage Plasmodium and its hypnozoites.

[0049] In the seventh aspect of the present invention, there is provided the use of the outer membrane vesicles of the present invention, the composition of the present invention or the complex of the present invention in the preparation of a product for loading and / or delivering drugs for preventing or treating diseases; preferably, the product is a vaccine.

[0050] In one or more embodiments, the disease comprises tumor, infection, allergy, anemia, hypertension, depression, convulsion, bacterial infection, fungal infection, viral infection, rheumatism, parasites, malaria, immune system disease, nervous system disease, diabetes, epilepsy, bleeding, hyperosmosis, glaucoma, sedation, toxin, anesthesia.

[0051] In one or more embodiments, the disease is malaria, in particular malaria associated with Plasmodium and its hypnozoites.

[0052] In one or more embodiments, the disease is malaria associated with hepatic stage Plasmodium and its hypnozoites, in particular parasitemia associated with hepatic stage Plasmodium and its hypnozoites.

[0053] In one or more embodiments, the malarial parasite is a malarial parasite that uses malarial parasite-susceptible insects, rodents, primates, poultry or birds as hosts; preferably includes: Plasmodium falciparum, Plasmodium berghei, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, Plasmodium brasilianum, Plasmodium cynomolgi, Plasmodium knowlesi, Plasmodium schwetzi, Plasmodium simium, Plasmodium chabaudi, Plasmodium yoelii, Plasmodium spp. yoelii), Plasmodium gallinaceum, Plasmodium relictum.

[0054] In one or more embodiments, the malarial parasite is a malarial parasite that uses a malarial parasite-susceptible mosquito as a host; preferably, the malarial parasite-susceptible mosquito includes: Anopheles gambiae and Aedes gambiae.

[0055] In the eighth aspect of the present invention, a method for inhibiting Plasmodium is provided, comprising: using the isolated outer membrane vesicles (OMV) of the present invention, the composition of the present invention or the complex of the present invention to deliver drugs that inhibit Plasmodium, or using the pharmaceutical composition of the present invention for inhibition.

[0056] In the ninth aspect of the present invention, a kit / medicine box for inhibiting Plasmodium or preventing and treating diseases related to Plasmodium infection is provided, comprising: the isolated outer membrane vesicles described in the present invention; the composition described in the present invention; the pharmaceutical composition described in the present invention; or the complex described in the present invention, or a combination thereof.

[0057] In the tenth aspect of the present invention, there is provided a use of intestinal bacteria derived from blood-sucking insects or a culture thereof for preparing outer membrane vesicles (OMV); preferably, the intestinal bacteria derived from blood-sucking insects include intestinal bacteria derived from Anopheles or Aedes; more preferably, the intestinal bacteria include Serratia.

[0058] In one or more embodiments, the intestinal bacteria include: Serratia ureilytica, Serratia marcescens, Serratia rubidaea, Serratia liquefaciens, Serratia plymuthica, Serratia ficaria, Serratia grimesii, Serratia fonticola, etc.

[0059] In one or more embodiments, the intestinal bacteria is Su_YN1, which is a strain with the deposit number CGMCC No.18971.

[0060] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 , Transmission electron microscopy image of Anopheles midgut section, showing that blood-induced intestinal bacteria Su_YN1 produces a large amount of OMVs in the mosquito gut.

[0062] Figure 2 , Comparison of electron microscopy results of OMV production induced by Su_YN1 by different blood components.

[0063] Figure 3 , Comparison of electron microscopy results of OMV production induced by Su_YN1 with sera from different sources. Figure 3 Left: Transmission electron microscopy results; Figure 3 Right: Quantitative analysis results. Arrows indicate OMVs.

[0064] Figure 4 , SEM observation results of serum-induced OMV production by Su_YN1. Figure 4 Left) represents scanning electron microscopy; TEM ( Figure 4 Right) represents transmission electron microscopy.

[0065] Figure 5 , analysis of the homogeneity of OMV production by Su_YN1 with or without serum induction. Figure 5 Top: Transmission electron microscopy observation results; Figure 5 Lower left: Quantitative analysis results of serum-free induction group; Figure 5 Lower right: Quantitative analysis results of the serum-induced group.

[0066] Figure 6 , the effect of different culture temperatures on serum-induced Su_YN1 production of OMVs.

[0067] Figure 7 , OMV production of different strains under serum induction conditions.

[0068] Figure 8 , the effects of different OMV quantification methods on serum-induced OMV production by Su_YN1. Figure 8 The above are respectively based on the BCA method ( Figure 8 Upper left), Kdo content determination method ( Figure 8 Upper middle) and total lipid determination ( Figure 8 Upper right) Results of quantification of OMVs. Figure 8 The lower left is the particle size distribution analysis result of OMV particles; Figure 8 The lower right is a state diagram of a representative OMV precipitate.

[0069] Fig. 9 , Characteristic analysis of OMV production by strain Su_YN1 in response to serum induction. Fig. 9 Left is the OMV yield under different serum concentration culture conditions; Fig. 9 Right is the concentration of OMV at different culture times.

[0070] Fig.10 , comparison results between the traditional method and the preparation method of the present invention.

[0071] Fig.11 Comparative analysis of the lipidomes of serum-induced OMVs (FBS+OMVs), serum-free OMVs (FBS-OMVs) and E. coli K12W3110 strain OMVs (K12 OMVs). Fig.11 The above is a cluster analysis of the components in OMVs lipids. Fig.11 The lower left and lower middle are the bar chart and pie chart of the lipid component proportions in serum-induced OMVs (FBS+OMVs), Fig.11The lower right is the principal component analysis (PCA) results of lipids in OMVs. PC: phosphatidylcholine, DG: diacylglycerol, PE: phosphatidylethanolamine, LPC: lysophosphatidylcholine, SM: sphingomyelin, So: sphingosine, PS: phosphatidylserine, Cer: ceramide, TG: triacylglycerol, phSM: phytosphingosine, TG: triacylglycerol, PG: phosphatidylglycerol, AHex: acylhexosylceramide.

[0072] Fig.12 , E.coli K12 W3110 strain OMV (E.coli W3110 OMV) and Su_YN1 OMV proteome analysis induced by the serum of the present invention. Fig.12 The upper left and upper right are bar graphs showing the proportion of protein sources from E. coli W3110 OMV and Su_YN1 OMV, respectively. Fig.12 The following is the protein composition of Su_YN1 OMV induced by the serum of the present invention.

[0073] Fig.13 , OMV binds to the antimalarial protein AmLip and mediates antimalarial activity. Fig.13 The upper left is a western blot analysis of the distribution of AmLip antimalarial protein in the culture supernatant of Su_YN1, the supernatant after OMV removal, and the purified OMV; Fig.13 The upper right is the immunoelectron microscopy detection image of AmLip protein on the surface of OMV. Fig.13 The lower left is the analysis of the antimalarial activity of culture supernatant, culture medium with OMV removed, and purified OMV against Plasmodium berghei (Pb ANKA); Fig.13 Lower right is the antimalarial activity analysis of AmLip knockout OMV against Plasmodium berghei (Pb ANKA).

[0074] Fig.14 , Su_YN1 OMV delivers AmLip to enter and lyse Plasmodium cells. Fig.14 Left: Indirect immunofluorescence detection of OMV and AmLip protein distribution of Plasmodium falciparum Pf3D7 iRBC after OMV treatment; Fig.14 Right: Indirect immunofluorescence detection of host cell membrane and Plasmodium PVM membrane integrity by Pf3D7 iRBC after OMV treatment.

[0075] Fig.15 , Su_YN1 OMV quickly enters the malarial parasite through the PC uptake pathway. Fig.15 The upper left is the detection of the ability of OMVs from different sources to enter Plasmodium; Fig.15 The upper right is the PC-dependent uptake pathway of OMV into Plasmodium; Fig.15 Below is live cell imaging analysis of OMV entry into Pf3D7iRBCs.

[0076] Fig.16 , Determination of Su_YN1 OMV LPS content produced under serum induction conditions (Kdo method).

[0077] Fig.17 , in vivo toxicity and tolerance testing of Su_YN1 OMV prepared by serum induction. Fig.17 Left is the analysis of mouse survival rate after OMV injection; Fig.17 The right side shows that after animals were injected with W3110 OMV and Su_YN1 OMV, there was no significant change in the serum TNFα of the animals.

[0078] Fig.18 The effect of Su_YN1 OMV prepared by serum induction on mouse organs. The upper figure is a comparison of liver and kidney organs 2h and 16h after administration of PBS, W3110 OMV, and Su_YN1 OMV. The lower figure is a hematoxylin-eosin (HE) staining of liver and kidney tissue cells after administration of PBS, W3110 OMV, and Su_YN1 OMV.

[0079] Fig.19 , organ distribution of Su_YN1 OMV prepared by serum induction in vivo.

[0080] Fig. 20 , before and after comparison of serum-induced Su_YN1 OMV loaded with primaquine (PQ). Fig. 20 Top: morphology of primaquine (PQ) standard solution, OMV solution, and primaquine-bound OMV (OMV-PQ) solution; Fig. 20 Bottom: HPLC identification of primaquine (PQ) standard, OMV sample, and Su_YN1 OMV sample extract combined with primaquine (OMV-PQ).

[0081] Fig.21 , primaquine (PQ) standard, and HPLC-mass spectrometry (primary and secondary) identification results of Su_YN1 OMV samples combined with primaquine (OMV-PQ).

[0082] Fig. 22 , Su_YN1 OMV primaquine (PQ) prepared by serum induction can be used to treat liver-stage Plasmodium infection in mice. Fig. 22 The above is a schematic diagram of the process of animal experiments. Fig. 22 Below is the proportion of animals developing parasitemia after injection of OMV-PQ and PQ. DETAILED DESCRIPTION

[0083] After in-depth research, the inventors provide a method for preparing outer membrane vesicles (OMVs), and also provide outer membrane vesicles (OMVs) prepared by the method, compositions thereof, pharmaceutical compositions, and their use in preparing drugs for preventing diseases (such as preparing vaccines) and treating diseases (such as malaria associated with liver-stage Plasmodium and its hypnozoites).

[0084] OMV of the present invention and its use

[0085] As used in the present invention, the "outer membrane vesicle", "outer membrane vesicle", "OMV" or "OMVs" refers to a substance secreted by bacteria into the external environment, usually with a diameter of 50-300nm and a double-membrane bubble structure. OMV mainly contains components of the bacterial outer membrane such as phospholipids, outer membrane proteins, and lipopolysaccharides, and may also contain a small amount of components in the periplasm, inner membrane, and even the cytoplasm. According to the preparation source of bacterial OMV, OMV is mainly divided into spontaneously produced OMV (sOMV, spontaneous released OMV), OMV (dOMV, Detergent extracted OMVs) obtained by stimulating bacterial culture with various detergents, and OMV (eOMV) produced by stimulating bacterial culture with non-detergent methods such as EDTA.

[0086] The “traditional process”, “traditional method” or “traditional method for preparing OMV” mentioned in the present invention refers to the use of detergents (dOMV) or non-detergent methods such as EDTA (eOMV) to stimulate bacteria to obtain OMV.

[0087] The OMV of the present invention contains lipids and proteins. The lipid content of OMV is analyzed, and cluster analysis shows that it is enriched with major lipids such as phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylethanolamine (PE), and also contains some glycerophospholipids.

[0088] OMVs can be isolated, meaning they are physically separated, in whole or in part, from the environment in which they were synthesized. The isolation can be based on weight (or mass), density (including buoyant density), size, color (e.g., where the encapsulation of the OMVs is detectable by their energy emission), etc.

[0089] As used in the present invention, the "OMV" can be used to prepare drugs for preventing and treating diseases. From another perspective, the present invention provides the use of OMV in preparing drugs for preventing and treating diseases. It can also be said that the "OMV" of the present invention is used to prevent and treat diseases, that is, the "OMV" of the present invention is an OMV for preventing and treating diseases. In other words, the present invention provides a method for preventing and treating diseases, the method comprising: using the OMV described in the present invention.

[0090] As used in the present invention, the "OMV" can be prepared for loading and / or delivering drugs for preventing and treating diseases. That is, the "OMV" is an OMV for loading and / or delivering drugs for preventing and treating diseases. From another perspective, the present invention provides the use of OMV in preparing products for loading and / or delivering drugs for preventing and treating diseases.

[0091] As used in the present invention, the "loading and / or delivery" may refer to OMVs having void volume in their cores and / or they may contain one or more drugs between their cores and / or adjacent (or juxtaposed) lipid bilayers. Drugs are typically contained in lipid solutions during synthesis and are integrated (e.g., by encapsulation) into OMVs during synthesis in this manner. Lipophilic molecules may also be directly integrated into lipid bilayers when forming OMVs, or molecules with lipophilic tails may be anchored to lipid bilayers during OMV formation. OMVs may be generated in the absence of harsh solvents (e.g., organic solvents), and therefore, they may encapsulate a variety of drugs, including those susceptible to organic solvents, etc.

[0092] As used in the present invention, the "loading and / or delivery" may also refer to the formation of a complex between OMV and the drug, and the loading and / or delivery is completed in this manner. In one preferred embodiment of the present invention, Su_YN1 secretes a lipase protein AmLip (CN114381445A) with antimalarial activity, and the secreted AmLip protein binds to OMV to form an OMV-AmLip complex, thereby producing a delivery effect.

[0093] As described in the present invention, the present invention also provides a complex, which comprises the isolated outer membrane vesicle (OMV) described in the present invention and a lipase; preferably, the lipase is AmLip, or a fragment, derivative and analog thereof, more preferably, the AmLip comprises a protein having an amino acid sequence as shown in SEQ ID NO:2; or, a derivative protein having an amino acid sequence with more than 90% sequence identity with SEQ ID NO:2 and having the function of the protein shown in SEQ ID NO:2.

[0094] As used in the present invention, the term "AmLip" refers to a polypeptide isolated from Serratia or a conservative variant polypeptide or homolog thereof, which has lipolytic activity.

[0095] In a preferred embodiment of the present invention, the AmLip includes a polypeptide selected from the amino acid sequence shown in SEQ ID NO: 2. The term also includes variant forms of the polypeptide of the amino acid sequence shown in SEQ ID NO: 2 having the same function as the AmLip. These variant forms include (but are not limited to): deletion, insertion and / or substitution of one or more (usually 1-50, preferably 1-30, more preferably 1-20, more preferably 1-10, and most preferably 1-5) amino acids, and addition or deletion of one or several (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when amino acids with similar or similar properties are substituted, the function of the polypeptide is usually not changed. For example, adding or deleting one or several amino acids at the C-terminus and / or N-terminus usually does not change the function of the polypeptide; for another example, only expressing the catalytic domain, Helix domain and β-roll domain of the protein without expressing the carbohydrate binding domain can also obtain the catalytic function of the complete protein. Therefore, the term also includes active fragments and active derivatives of the AmLip. For example, the variation may occur outside the conserved functional domain of the polypeptide of the amino acid sequence shown in SEQ ID NO:2.

[0096] Variant forms of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that can hybridize with the AmLip DNA under high or low stringency conditions, and polypeptides or proteins obtained using anti-AmLip antibodies. The present invention also provides other polypeptides, such as fusion proteins comprising the AmLip or its fragments. In addition to almost full-length polypeptides, the present invention also includes fragments of the AmLip. Generally, the fragment has at least about 10 consecutive amino acids of the AmLip sequence, usually at least about 30 consecutive amino acids, preferably at least about 50 consecutive amino acids, more preferably at least about 80 consecutive amino acids, and most preferably at least about 100 consecutive amino acids.

[0097] The present invention also provides analogs of the AmLip protein or polypeptide. The difference between these analogs and the natural AmLip may be a difference in amino acid sequence, or a difference in modification form that does not affect the sequence, or both. These polypeptides include natural or induced genetic variants. Induced variants can be obtained by various techniques, such as random mutagenesis by radiation or exposure to mutagens, or by site-directed mutagenesis or other known molecular biological techniques. Analogs also include analogs with residues different from natural L-amino acids (such as D-amino acids), and analogs with non-natural or synthetic amino acids (such as β, γ-amino acids). It should be understood that the polypeptides of the present invention are not limited to the representative polypeptides exemplified above.

[0098] In some embodiments, the amino acid sequence of the variant form, fragment, derivative and analog of the AmLip protein has 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 2 and has the function of the protein shown in SEQ ID NO: 2. It is also called a derivative protein of the AmLip protein.

[0099] Serratia ureilytica Su_YN1 strain AmLip protein sequence (NC), 614aa

[0100] (SEQ ID NO:2)

[0101] The AmLip protein also includes variant forms, fragments, derivatives and analogs, functional domains, tags, signal peptides, polynucleotide forms, applications, compositions, preparations, kits, etc. of the AmLip, see patent CN114381445A, the entire contents of CN114381445A are incorporated herein in their entirety.

[0102] As used in the present invention, the drug for preventing a disease may be a vaccine. It can also be said that the OMV of the present invention exists in the vaccine in the form of an adjuvant.

[0103] As used in the present invention, the diseases include tumors, infections, allergies, anemia, hypertension, depression, convulsions, bacterial infections, fungal infections, viral infections, rheumatism, parasites, malaria, immune system diseases, nervous system diseases, diabetes, epilepsy, hemorrhage, hyperosmosis, glaucoma, sedation, toxins, anesthesia, etc. Preferably, the disease is malaria, more preferably malaria associated with Plasmodium and its hypnozoites, most preferably malaria associated with liver-stage Plasmodium and its hypnozoites, especially parasitemia of liver-stage Plasmodium and its hypnozoites.

[0104] As used in the present invention, the diseases, from another classification perspective, include cardiovascular-related diseases, liver-related diseases, kidney-related diseases, muscle-related diseases, brain-related diseases, lung-related diseases, intestinal (including small intestine, duodenum, jejunum, ileum, large intestine)-related diseases, spleen-related diseases, stomach-related diseases, pancreas-related diseases, reproductive system-related diseases, endocrine system-related diseases, nervous system-related diseases, bone-related diseases, etc.

[0105] As used in the present invention, the host of the "Plasmodium" includes organisms that can be attached to, infected by, or coexist with Plasmodium; in some specific embodiments, the Plasmodium host is, for example, mosquitoes, humans, rodents, primates, birds, etc. In some preferred embodiments, the host of the "Plasmodium" includes Plasmodium-susceptible mosquitoes; preferably, the Plasmodium-susceptible mosquitoes include: Anopheles gambiae and Aedes aegypti.

[0106] Preparation method of OMV of the present invention

[0107] As used in the present invention, the preparation method of "OMV" comprises the following steps: (i) culturing intestinal bacteria from blood-sucking insects in a culture medium so that the bacteria release vesicles into the culture medium; and (ii) collecting the vesicles in the culture medium. The vesicles are collected by size separation (such as filtering with a filter that allows vesicles to pass but does not allow intact bacteria to pass), and can be conveniently collected after centrifugation to preferentially precipitate cells relative to smaller vesicles (such as low-speed centrifugation).

[0108] In one or more embodiments, the whole blood and serum may be derived from animals. In another one or more embodiments, the whole blood and serum may also be in the form of extracts or substitutes for industrial applications. The "whole blood and serum extracts" refer to substances extracted, purified or derived from whole blood or serum. Serum substitutes are cell culture products that replace serum; the components of serum substitutes include amino acids, metabolites, vitamins, trace elements, buffering capacity, recombinant growth factors, carbohydrates, etc., which are artificially prepared and have a fixed composition, but can replace animal-derived serum when used for culture.

[0109] In one or more embodiments, the preparation method comprises one or more of the following AH:

[0110] A. The culture temperature of the culture medium for culturing bacteria in step (i) is 15 to 33° C.;

[0111] B. The bacterial inoculation ratio in step (i) is seed solution: culture solution = 1:100, wherein the bacterial OD value of the seed solution is 1.0 OD to 3.0 OD, preferably 2.0 OD to 3.0 OD;

[0112] C. The culture time of the bacteria in the culture medium in step (i) is 10 to 80 hours;

[0113] D. The intestinal bacteria described in step (i) are Serratia ureilytica, Serratia marcescens, Serratia rubidaea, Serratia liquefaciens, Serratia plymuthica, Serratia aficaria, Serratia grimesii, Serratia fonticola, etc., preferably Su_YN1, more preferably the Su_YN1 is a strain with a deposit number of CGMCC No.18971 in the General Microbiological Center of China National Microbiological Culture Collection Administration, or the nucleotide sequence of 16S rDNA of the Su_YN1 is as shown in SEQ ID NO:1;

[0114] E. The intestinal bacteria in step (i) is Serratia ureilytica, preferably the Serratia ureilytica is from the intestine of the blood-sucking insect Anopheles; more preferably, the blood-sucking insect includes Anopheles and Aedes;

[0115] F. The serum in step (ii) is derived from mice, rats, humans, cattle, pigs, rabbits, sheep, horses, and chickens. Preferably, the bovine serum includes fetal bovine serum, newborn bovine serum, calf serum, and adult bovine serum; more preferably, the serum is fetal bovine serum (FBS);

[0116] G. The concentration of the serum in step (ii) is 5% to 20%, preferably 10%;

[0117] H. The method of collecting vesicles in step (iii) is to collect vesicles by filtration, centrifugation, or salting out; preferably, the filtration is performed using a filter, and / or the centrifugation is performed using a low-temperature centrifugation at 4°C; more preferably, the filtration is performed using a 0.2 μm filter; and / or the centrifugation is performed using an ultracentrifugation with a centrifugal force of 10000 g to 25000 g, and most preferably, the centrifugal force is 15000 g.

[0118] In a preferred embodiment of the present invention, the strain "Su_YN1" is a new strain of Serratia spp. with natural antimalarial activity, which has been biologically preserved by the inventors and its preservation number is CGMCC No.18971 (Su_YN1). It has the characteristics of Serratia ureilytica, and the nucleotide sequence of its 16S rDNA can be as shown in SEQ ID NO:1, also including variants of the sequence.

[0119] Su_YN1-16S rDNA (SEQ ID NO:1):

[0120]

[0121] For the biological characteristics, functions, culture methods, related variants, domestication, bioengineering / genetic engineering modifications, preparation, uses, etc. of the Su_YN1 strain, please refer to patent CN114306391A, and the entire contents of CN114306391A are incorporated herein in their entirety.

[0122] From another perspective, the present invention provides a use of Serratia or a culture thereof for: preparing outer membrane vesicles (OMV); preferably, the Serratia is Serratia ureilytica; more preferably, the Serratia is Su_YN1; most preferably, the Serratia includes: a strain with a deposit number of CGMCC No.18971 in the General Microbiological Center of the China National Microbiological Culture Collection; or, the nucleotide sequence of 16S rDNA of the Serratia Su_YN1 is as shown in SEQ ID NO:1.

[0123] As used in the present invention, the preparation method of the present invention does not include a pre-concentration step. The pre-concentration of the present invention includes ultrafiltration concentration or detergent precipitation concentration, preferably wherein the detergent is trichloroacetic acid (TCA).

[0124] As used in the present invention, the "OMV" prepared by the preparation method of the present invention does not need to be dialyzed or gradient purified.

[0125] As described in the present invention, the prepared OMV can be quantitatively detected by a BCA quantitative method based on total protein, and / or a Kdo quantitative method based on LPS content, and / or a quantitative method based on total lipid content. An NTA particle analyzer can also be used for intuitive particle analysis.

[0126] As described in the present invention, the prepared OMVs can be used to detect and / or identify lipid components through lipidome cluster analysis.

[0127] The present invention also provides OMV prepared according to the preparation method of the present invention.

[0128] Compositions, pharmaceutical compositions and uses of OMV of the present invention

[0129] The present invention provides a composition comprising OMVs which are released into the culture medium during the bacterial culture of the present invention. Such a composition preferably does not comprise any live and / or intact bacteria. Such a composition can be used for vaccine preparation.

[0130] The present invention also provides a pharmaceutical composition comprising a therapeutic agent and / or a diagnostic agent, the isolated OMVs of the present invention and a pharmaceutically acceptable excipient.

[0131] As used herein, "pharmaceutically acceptable excipients" are well known in the art. Suitable excipients are typically large, slowly metabolized macromolecules such as proteins, carbohydrates, polylactic acid, polyglycolic acid, polymerized amino acids, amino acid copolymers, sucrose, trehalose, lactose, and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art. The vaccine may also contain a diluent such as water, saline, glycerol, etc. In addition, adjuvants such as wetting agents or emulsifiers, pH buffers, etc. may be present. Sterile, pyrogen-free, phosphate-buffered saline is a typical carrier.

[0132] As used in the present invention, the therapeutic agent can be a prodrug that is metabolized in vivo to be converted into its active (and / or stable) form. The therapeutic agent can occur naturally or non-naturally. Naturally occurring therapeutic agents include those that can be synthesized by the subject to which the OMV is administered. Non-naturally occurring ones are those that are not normally naturally occurring, whether produced by plants, animals, microorganisms or other living organisms.

[0133] In one embodiment of the present invention, OMVs can have void volume at their core and / or they can contain one or more therapeutic agents and / or diagnostic agents between their core and / or adjacent (or juxtaposed) lipid bilayers. Therapeutic agents and / or diagnostic agents are usually contained in lipid solutions during synthesis, and are integrated (e.g., by encapsulation) into OMVs during synthesis in this way. Lipophilic molecules can also be directly integrated into lipid bilayers when forming OMVs, or molecules with lipophilic tails can be anchored to lipid bilayers during OMV formation. OMVs can be generated in the absence of harsh solvents (e.g., organic solvents), so they can encapsulate a variety of therapeutic agents and / or diagnostic agents, including those susceptible to organic solvents, etc.

[0134] The OMV of the present invention can encapsulate one or more therapeutic agents selected from the following: anti-tumor drugs, anti-infective agents, anti-allergic agents, anti-anemic drugs, angiogenesis inhibitors, β-adrenergic blockers, calcium channel antagonists, antihypertensive drugs, antidepressants, anticonvulsants, antibacterial drugs, antifungal drugs, antiviral drugs, antirheumatic drugs, antiparasitic drugs, antimalarial drugs, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, antidiabetic drugs, antiepileptic drugs, anti-hemorrhagic drugs, anti-hyperosmotic drugs, anti-glaucoma drugs, immunomodulatory cytokines, sedatives, chemokines, vitamins, toxins, anesthetics, imaging agents and combinations thereof.

[0135] As one mode of the present invention, the encapsulated therapeutic agent is an antimalarial drug for treating liver-stage malarial parasites and their dormant subspores, in particular an antimalarial drug for treating parasitemia of liver-stage malarial parasites and their dormant subspores. Further, antimalarial drugs include artemisinin antimalarials and aminoquinoline antimalarials. The artemisinin antimalarials include but are not limited to artemisinin, artesunate, artemether, dihydroartemisinin or arteether. The aminoquinoline antimalarials include but are not limited to chloroquine, chloroquine phosphate, piperaquine, primaquine or primaquine phosphate. As a preferred mode of the present invention, the encapsulated therapeutic agent is primaquine (Primaquine, PQ).

[0136] The diagnostic agent of the present invention refers to a variety of reagents for detection or diagnosis purposes, including but not limited to imaging agents, immunomodulators (such as immunostimulants and immunosuppressants), antigens, adjuvants, cytokines, chemokines, anticancer agents, anti-infective agents, nucleic acids, antibodies or fragments thereof, fusion proteins (such as cytokine-antibody fusion proteins, Fc fusion proteins), etc. As a preferred embodiment of the present invention, the encapsulated diagnostic agent is a reagent for diagnosing malaria associated with hepatic stage Plasmodium and its hypnozoites. As a preferred embodiment of the present invention, the diagnostic agent is a reagent for diagnosing parasitemia associated with hepatic stage Plasmodium and its hypnozoites.

[0137] The amount of therapeutic agent and / or diagnostic agent encapsulated in OMV can be different, and can depend on the properties of therapeutic agent and / or diagnostic agent. As shown in the examples, 1-100 μg of therapeutic agent (such as PQ) and / or diagnostic agent can be encapsulated per 100 μg OMV. In some embodiments, 2-50 μg of therapeutic agent and / or diagnostic agent can be encapsulated per 100 μg OMV. In some embodiments, 5-20 μg of therapeutic agent and / or diagnostic agent can be encapsulated per 100 μg OMV. In some preferred embodiments, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg, 10 μg, 11 μg, 12 μg, 13 μg, 14 μg, 15 μg, 16 μg, 17 μg, 18 μg, 19 μg or 20 μg of therapeutic agent and / or diagnostic agent can be encapsulated per 100 μg OMV.

[0138] The OMVs of the present invention may also be characterized by retention properties, i.e., under certain conditions (e.g., when placed in a serum-containing matrix) and maintained at a certain temperature (e.g., 22-30° C.), the OMVs may release the therapeutic and / or diagnostic agent at a specific rate.

[0139] The present invention provides the use of OMV in the preparation of a drug for treating and / or preventing malaria. Specifically, the malaria may be an infection with Plasmodium. It can also be said that the OMV of the present invention can be used to prepare a drug for treating and / or preventing malaria; or, the OMV of the present invention can be used to treat and / or prevent malaria; or, the present invention provides a method for treating and / or preventing malaria, comprising using the OMV of the present invention.

[0140] It should be noted that the therapeutic agent and / or diagnostic agent and the isolated OMV described in the present invention can be administered simultaneously, sequentially, separately, or in combination. As long as they can produce the effect of preventing and / or treating the disease, or enable OMV to load and / or deliver the therapeutic agent and / or diagnostic agent, they can achieve the purpose of the present invention and are within the scope of protection of the present invention.

[0141] The present invention provides a method for inhibiting malarial parasites, comprising: using the outer membrane vesicles (OMV) of the present invention, the composition of the present invention or the complex of the present invention to deliver drugs for inhibiting malarial parasites, or using the pharmaceutical composition of the present invention for inhibition.

[0142] The present invention provides a method for improving the resistance of a malarial parasite vector host to malarial parasite infection, comprising: administering the pharmaceutical composition of the present invention, the composition containing OMV of the present invention, or the complex of the present invention to the malarial parasite host.

[0143] As used in the present invention, the malarial parasite is a malarial parasite that uses malarial parasite susceptible insects, rodents, primates, poultry or birds as hosts; preferably includes: Plasmodium falciparum, Plasmodium berghei, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, Plasmodium brasilianum, Plasmodium cynomolgi, Plasmodium knowlesi, Plasmodium schwetzi, Plasmodium simium, Plasmodium chabaudi, Plasmodium yoelii, Plasmodium gallinulae, Plasmodium spp. gallinaceum, Plasmodium relictum; preferably, the malarial parasite is a malarial parasite that uses a malarial parasite-susceptible mosquito as a host; more preferably, the malarial parasite-susceptible mosquito includes: Anopheles gambiae and Aedes gambiae.

[0144] As used in the present invention, the term "inhibiting malarial parasites" includes: antagonizing malarial parasites, killing malarial parasites, blocking malarial parasite infection, blocking malarial parasite transmission, blocking malarial parasite reproduction, blocking malarial parasites from entering an environment or state suitable for their survival / proliferation, etc. The term "inhibiting" also includes "preventing and controlling".

[0145] As used in the present invention, the term “containing”, “having” or “includes” includes “comprising”, “mainly consisting of”, “substantially consisting of”, and “consisting of”; “mainly consisting of”, “substantially consisting of” and “consisting of” are subordinate concepts of “containing”, “having” or “including”.

[0146] The present invention also provides a kit / medicine box for inhibiting Plasmodium or preventing and treating diseases related to Plasmodium infection, which comprises: the outer membrane vesicle (OMV) described in the present invention; the composition described in the present invention; the pharmaceutical composition described in the present invention, or the complex described in the present invention; or a combination thereof.

[0147] As used in the present invention, OMVs may be preserved and stored in a kit until needed.

[0148] The main advantages of the present invention are:

[0149] The rapid serum induction method and related technologies provided by the present invention are used to prepare OMVs, which have the following advantages in preparation:

[0150] 1) With extremely high OMV yield, the volume of fermentation broth required for bacterial culture and OMV separation and purification is significantly reduced, the fermentation difficulty is reduced, and subsequent further purification is easier. Taking BCA quantification as a reference, under physiological conditions without genetic modification or stimulation by detergents, the OMV yield of the commonly used LB-based E. coli K12 strain is generally between 100-200 μg / L, which is much lower than the yield of the Su_YN1 strain OMV based on serum culture conditions of the present invention, which is generally 20-40 mg / L.

[0151] 2) The fermentation culture time is significantly shortened. The strains and techniques provided by the present invention have the performance of rapid production of OMVs, and a large yield can usually be obtained in 20 hours. Extending the fermentation time can further increase the production capacity of OMVs, and the fermentation cost is lower. The commonly used LB-based E. coli K12 strain is generally used for 3-5 days for the fermentation culture of large quantities of OMVs.

[0152] 3) The preparation of OMV is more efficient. Our technical method makes the pre-treatment of crude OMV extracts easier because no detergents or other ingredients are introduced. Thanks to the improvement of OMV yield and quality, no pre-treatment operations such as ultrafiltration concentration and salting out are required during preparation. The obtained OMV activity loss is small, the overall efficiency of the preparation process is significantly improved, and the cost is significantly reduced.

[0153] The OMV obtained by the present invention has the typical morphological characteristics of bacterial outer membrane vesicles, but has many advantages in performance that traditional OMV does not have:

[0154] 1) High eukaryotic cell compatibility and targeting ability. The OMVs produced by serum induction have a special lipid group similar to that of the serum source, making the membrane lipid group of the OMVs closer to the lipid composition of the eukaryotic cell membrane and easier to fuse with eukaryotic cells. Therefore, compared with the OMVs prepared by the existing method, the OMVs prepared by the present invention have significantly stronger eukaryotic cell targeting ability.

[0155] 2) It has low systemic toxicity. The proportion of bacterial outer membrane proteins and bacterial-derived lipid components on the OMV prepared by this method is lower, and the content of endotoxin LPS is significantly reduced. Therefore, the OMV prepared by this method has lower immunogenicity and toxicity to eukaryotic cells. In the mouse model, the OMV prepared by the present invention showed lower immunostimulation, better tolerance, lower toxic and side effects, and significantly reduced organ accumulation and damage. Unlike the OMV prepared by the traditional method derived from E. coli, which causes acute toxicity and death in mice, the OMV of the present invention has good survival in mice even under high-dose conditions, without obvious irreversible kidney and liver damage, showing higher safety.

[0156] 3) It has efficient drug loading capacity. The OMV prepared by the strain and method provided by the present invention integrates a large amount of serum lipids and protein components, such as serum glycolipids and serum albumin, and has the special performance of drug loading. It can be used as a nanocarrier to load drugs and therapeutic molecules (proteins and nucleic acids) of various properties. Compared with traditional OMV, it has stronger loading compatibility. On the one hand, it can be used to load fat-soluble drugs and drugs with serum albumin binding. For example, the present invention provides a technical reference to enable hemin, paclitaxel and primaquine to be quickly and efficiently loaded onto OMV. On the other hand, through the genetic engineering of bacteria, specific drugs can be selectively loaded by expressing specific drug transport proteins.

[0157] In summary, the preparation of outer membrane vesicles (OMVs) based on the serum induction technology of the present invention combined with specific strains has high efficiency advantages in terms of yield, efficiency and quality. The obtained OMVs not only contain serum-derived lipid and protein components, have more excellent targeting properties and low in vivo toxicity, but also have great potential for further transformation and expansion, have great application potential in medical treatment and diagnosis, and have broad application prospects.

[0158] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, 3rd Edition, Science Press, or according to the conditions recommended by the manufacturer.

[0159] Example 1: Blood components induce the production of OMVs by Anopheles gut symbiotic bacteria Su_YN1

[0160] The inventors studied the colonization of Serratia ureilytica Su_YN1 (see patent CN114306391A, the deposit number of Su_YN1 is CGMCC No.18971, and the 16S rDNA sequence is shown in SEQ ID NO: 1) in Anopheles mosquitoes and unexpectedly found that Su_YN1 produced a large number of outer membrane vesicles (OMV) in the intestines of blood-sucking Anopheles mosquitoes, while Su_YN1 in the intestines of Anopheles mosquitoes that sucked sugar water did not have this phenomenon ( Figure 1 ), indicating that blood induced Su_YN1 to produce a large amount of OMV.

[0161] In order to determine whether blood induced the generation of Su_YN1 outer membrane vesicles and which blood components induced the production of OMVs, the inventors further divided the blood components into three components: whole blood, red blood cell (RBC) lysate, and serum, and co-cultured them with Su_YN1 in vitro. In order to simulate the in vivo conditions, RPMI 1640 medium was used as the basal medium to add the above components and co-culture with Su_YN1. After culturing at 30°C for 24 hours, the culture supernatant was collected and the OMV generation was detected by transmission electron microscopy.

[0162] The results showed that whole blood and serum could significantly induce the production of OMVs, while RBC lysate could not induce OMV production ( Figure 2 ), indicating that serum components in the blood are the key factors in promoting Su_YN1 to produce OMVs.

[0163] Example 2: Serum from different sources can induce Su_YN1 to produce OMVs

[0164] In order to verify whether sera from different sources can induce Su_YN1 to produce OMVs, the inventors tested the ability of mouse serum, human serum, bovine serum and porcine serum to induce Su_YN1 to produce OMVs. In order to eliminate interference, the inventors first ultracentrifuged sera from different sources to remove exosomes and other vesicles contained in the serum, and then co-cultured the treated sera to induce Su_YN1 to produce OMVs. Transmission electron microscopy of the culture supernatant confirmed that sera from different sources can induce OMV production ( Figure 3 , left), after purifying OMVs and conducting quantitative analysis, it was found that sera from different sources have the ability to induce Su_YN1 to produce OMVs ( Figure 3 , right side).

[0165] In subsequent experiments, in order to ensure the repeatability and stability of the experimental results, the inventors used commercial fetal bovine serum (FBS) to induce Su_YN1 to produce OMVs for analytical testing.

[0166] Example 3: Serum-induced Su_YN1 produces vesicles derived from bacterial outer membrane

[0167] In order to further determine the source of OMVs produced by Su_YN1 and exclude the interference of exosomes and other components in serum, the FBS (pre-exosomes were removed by ultracentrifugation)-induced Su_YN1 bacterial culture samples were observed by scanning electron microscopy and transmission electron microscopy. Scanning electron microscopy showed that a large number of OMVs were produced from the bacterial outer membrane, shed and scattered around the bacteria ( Figure 4 , SEM on the left), and the sectioned samples were subjected to transmission electron microscopy analysis, which clearly showed the process of OMV bulging outward from the bacterial outer membrane and separating ( Figure 4 , TEM on the right).

[0168] These results confirmed that serum-induced Su_YN1 production vesicles were generated in the bacterial outer membrane.

[0169] Example 4: Serum-induced Su_YN1 produces OMVs with high homogeneity

[0170] The production of bacterial OMVs is affected by many factors, and the OMVs produced are heterogeneous in size. In order to further analyze the differences in the properties of OMVs produced by Su_YN1 with or without serum induction, the inventors prepared purified OMVs and further compared the properties of OMVs produced by Su_YN1 with or without FBS induction by transmission electron microscopy. It was found that under culture conditions without serum, Su_YN1 produced almost no OMVs, and the very small amount of OMVs produced were small in size (50-100nm), while the number of OMVs produced by Su_YN1 under serum induction increased greatly, and the average size increased significantly compared to that under serum-free induction conditions, reaching 100-150nm, which is consistent with the previous electron microscopy observations of whole bacterial samples. More importantly, compared with the uneven size distribution of OMVs induced by serum-free conditions, the size of OMVs under serum induction is uniform and concentrated ( Figure 5 ).

[0171] Example 5: Temperature has an important influence on serum-induced OMV production by Su_YN1

[0172] The inventors further tested the effect of different culture temperatures on serum-induced Su_YN1 production of OMVs. Three culture temperatures of 22°C, 30°C, and 37°C were selected for testing. The results showed that at 37°C and higher, the ability of Su_YN1 to produce OMVs was significantly inhibited. At 22-30°C, OMVs were produced at a higher yield ( Figure 6 ).

[0173] Example 6: Serum induces most intestinal bacteria from Anopheles and Aedes to produce large amounts of OMVs

[0174] During the electron microscopic observation and OMV property analysis, the inventors found that Su_YN1 bacteria produced a high yield of OMVs. It is speculated that the intestinal bacteria of blood-sucking vector insects have developed the ability to produce a large number of OMVs in the long-term co-evolution process under the influence of the insects' blood-sucking behavior. So we further compared the production of OMVs under serum-induced conditions in the intestinal bacteria of non-blood-sucking insects such as fruit flies, black soldier flies and bees, as well as some common pathogenic bacteria and laboratory engineered bacteria, and found that the ability of blood-sucking insect Anopheles gut bacteria to produce a large number of OMVs is universal. The results are shown in Tables 1 and Figure 7 As shown, the core symbiotic bacteria in the bee gut - Snodgrassella alvi, Lactobacillus (Firm4, Firm5), Bifido, the plant pathogenic bacteria - Erwinia carotovora, and human intestinal Escherichia coli (EPEC) do not have this ability ( Figure 7 ). Intestinal bacteria from Anopheles, Aedes, etc., including Su_YN1, Su_JS3, Ag2, Sm_26 (strain number, CGMCC No.18972) and other strains, all have excellent ability to produce OMVs in large quantities. Therefore, the present invention provides a method for obtaining bacteria with excellent outer membrane vesicle (OMV) production ability from blood-sucking vector insects. The blood-induced OMV method of the present invention can be used to prepare OMV vesicle materials from various intestinal bacteria.

[0175] Table 1 Comparison of OMV production of different pathogenic bacteria and engineered bacteria

[0176]

[0177] In order to further analyze the serum-induced OMV production of Su_YN1, the inventors collected the Su_YN1 supernatant and separated the OMVs for quantification after culturing at 30°C, 10% (v / v) FBS induction, and 200 rpm ventilation for 24 hours. The OMV quantification methods used include: BCA quantification of total protein, Kdo quantification based on LPS content, and quantification based on total lipid content. The OMV quantification results showed that FBS significantly induced Su_YN1 to produce a large number of OMVs ( Figure 8 superior).

[0178] Since different quantitative methods are all based on indirect quantification of the corresponding protein and lipid content, in order to more intuitively reflect the ability of Su_YN1 to produce OMVs under serum induction conditions, the inventors used NTA particle analyzer to analyze the particles of Su_YN1 culture supernatant with and without FBS induction conditions. It was found that each milliliter of Su_YN1 culture supernatant under FBS induction could produce 1-10 billion OMV particles ( Figure 8The results show that serum-induced Su_YN1 has excellent OMV production performance. In addition, the size of serum-induced OMV particles is uniform, and most of them are 100-150nm particles ( Figure 8 Lower left), compared with the previous electron microscopy observation results ( Figure 5 ), which further confirmed the credibility of the particle analysis results. Since serum-induced Su_YN1 has extremely excellent OMV production performance, 27 ml of induced supernatant can be directly ultracentrifuged to obtain OMV precipitates visible to the naked eye without pre-concentration treatment ( Figure 8 lower right).

[0179] Example 7: Serum induces Su_YN1 to rapidly produce OMVs

[0180] The characteristics of Su_YN1 in producing OMVs in response to serum induction in RPMI 1640 basal medium were further analyzed. First, the relationship between serum content and OMV production was analyzed. After inoculating Su_YN1 bacteria at a volume ratio of 1:100 in RPMI 1640 medium containing different FBS concentrations, aeration culture was performed at 200 rpm. It was found that the content of FBS serum in RPMI 1640 medium was positively correlated with the production of OMVs within a certain range. In the presence of a small amount of serum (5% (v / v)), Su_YN1 can produce more OMVs. The OMV production is the highest under the condition of 10% (v / v) serum. Increasing the serum content does not further promote OMV production ( Fig. 9 Left).

[0181] Furthermore, the relationship between culture time and OMV production of Su_YN1 strain was analyzed. After Su_YN1 bacteria were inoculated at a ratio of 1:100 in RPMI1640 medium containing 10% (v / v) FBS, aeration culture was performed at 200 rpm. As the culture time accumulated, the growth density of Su_YN1 bacteria increased rapidly. At 15 hours of culture, OMVs began to be produced, and after 18 hours, OMVs increased to the maximum yield ( Fig. 9 right).

[0182] In summary, it was found that suitable culture temperature (20-30°C), 10% (v / v) FBS serum and higher bacterial density were more conducive to the production of OMVs in large quantities by Su_YN1. Su_YN1 strain can produce a large amount of OMVs in a shorter culture time (about 20 hours).

[0183] Example 8: The serum-induced method for preparing OMV has the advantages of simple preparation process and low cost

[0184] In this example, E. coli K12 W3110 strain, which can also produce OMVs, was selected to compare with Su_YN1 to examine the ability of the two strains to spontaneously form OMVs in their respective culture media. The W3110 strain cannot grow normally under serum conditions, and the strain was isolated and prepared under LB culture conditions for OMVs.

[0185] The inventors first compared the difference in yield between obtaining OMVs by culturing W3110 using LB and obtaining OMVs by culturing Su_YN1 using serum induction provided by the present invention.

[0186] Cultivation of E. coli K12 W3110 strain: 1L of LB medium (without other additives), inoculate the bacterial liquid after activation culture for 20 hours with the strain at a ratio of 1:100, and culture for 3 days). Use after cultivation The OMVs were harvested by ultrafiltration and concentration to 30 ml using a Plus-70 centrifugal filter, and then the vesicles were obtained by ultracentrifugation.

[0187] Culture of Su_YN1: 30 ml of RPMI 1640 medium containing 10% (v / v) FBS serum, the bacterial liquid after activation culture for 20 hours was inoculated with the strain at a ratio of 1:100 and cultured for 24 hours.

[0188] The results showed that the yield of OMV produced by Su_YN1 was 100 to 400 times or more that of K12 W3110 strain, based on the protein content of OMV. The method of the present invention can produce up to 1 mg of OMV in only 30 ml of fermentation broth. After ultracentrifugation at 150,000 g for 1 hour, a large amount of grayish white translucent OMV precipitate was visible in the culture supernatant, and no pre-concentration step was required.

[0189] The inventors also observed the quality of the obtained OMVs. Compared with the E. coli K12 W3110 strain, the OMVs prepared by Su_YN1 had excellent size uniformity, which was significantly better than the existing methods and greatly facilitated the subsequent OMV refinement and purification steps.

[0190] Since serum-induced Su_YN1 OMV has a high yield, the preparation of OMV is greatly simplified, which not only helps to reduce the cost of OMV production, but also promotes the rapid acquisition and application of OMV in clinical practice. Based on the method and strain of the present invention, a method for efficiently and quickly preparing OMV is provided ( Fig.10 ).

[0191] Compared with the current method of preparing bacterial OMVs, the method of obtaining OMVs using Su_YN1 has the advantages of lower cost, faster speed, simple operation and better purity. First, due to the low yield of traditional preparation of OMVs, the preparation of crude OMV extracts requires a large amount of amplification culture, consumes a large amount of culture medium (usually measured in liters), and requires the treatment of a large amount of secondary waste. Based on the strain of the present invention, only a small amount of culture solution (tens of milliliters) is needed to obtain a large amount of crude OMV extracts, saving a lot of culture costs. Secondly, the traditional method of preparing OMVs requires long-term culture. For example, the preparation of E. coli OMVs requires 3 days of fermentation culture, while the use of the strain and culture method of the present invention only takes 15-20 hours, greatly saving the preparation cost. In addition, due to the low OMV yield and too low concentration in the primary culture medium in the traditional method, a high-cost pre-concentration step is required to increase the concentration of OMV in the culture medium before ultracentrifugation can be performed to prepare OMV crude extracts. However, due to the high OMV yield of the strain provided by the present invention, the OMV crude extract can be directly obtained by ultracentrifugation, which greatly simplifies the operation, reduces the processing steps, and prevents the loss of OMV yield and activity caused by operations such as ultrafiltration.

[0192] Example 9: OMVs prepared by serum-induced Su_YN1 have a lipid composition that is closer to eukaryotic properties

[0193] In order to study the special properties of OMVs produced by serum-induced Su_YN1, we first compared lipidome analysis to identify and compare the lipidome differences of OMVs from three different sources: OMVs produced by E. coli K12 W3110 strain (K12 OMVs), Su_YN1 OMVs collected under serum-free culture conditions (FBS-OMVs), and Su_YN1 OMVs prepared using the serum culture conditions technology of the present invention (FNS+OMVs). Lipidomic analysis found that this type of FBS+OMV has more abundant serum-derived lipids. Cluster analysis showed that it is enriched with major lipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), and sphingomyelin (SM). In addition, it also contains some glycerophospholipids ( Fig.11 ).

[0194] It is worth noting that this type of phospholipid structure is significantly different from the lipid structure of traditional bacterial-derived vesicles mainly composed of glycerophospholipids and LPS lipopolysaccharide, indicating that serum induction significantly reshaped the lipid composition of Su_YN1 OMV. This type of serum-induced Su_YN1 prepared OMV has a lipid composition that is closer to eukaryotic characteristics.

[0195] Example 10: OMVs prepared by serum-induced Su_YN1 have a special protein composition

[0196] In order to study the special protein composition of serum-induced Su_YN1 OMVs, the inventors analyzed the proteome of purified LB-cultured E. coli K12 OMVs and bovine serum-induced Su_YN1 OMVs. The results showed that the vast majority of peptides identified in the protein composition of E. coli K12 OMVs came from E. coli bacteria's own proteins, and very few proteins in the culture medium (such as yeast extract) were captured ( Fig.12 Only about 18.6% of the peptides identified in the Su_YN1 OMV protein composition were derived from Serratia Su_YN1 itself, and the vast majority of the peptides identified were derived from serum components (Bostaurus) ( Fig.12 above right).

[0197] Detailed identification of the protein composition of Su_YN1 OMV revealed that its bacterial-derived proteins were mainly outer membrane-derived proteins such as autotransporters, further confirming that it was indeed an outer membrane-derived vesicle ( Fig.12 The serum affinity proteins are mainly serum-derived proteins such as apolipoprotein and iron-binding protein, indicating that Su_YN1 OMV has a strong affinity for specific serum proteins ( Fig.12 It binds to certain serum proteins in large quantities, causing significant changes in the overall protein composition.

[0198] Example 11: Preparation of highly malarial parasite-targeting OMV using the present invention

[0199] Malaria is a eukaryotic parasitic infectious disease caused by Plasmodium. This example illustrates that the technology of the present invention can be used to prepare OMV materials with high eukaryotic targeting, and efficiently deliver anti-malarial active molecules into the eukaryotic parasite Plasmodium.

[0200] The inventors' previous studies found that Su_YN1 secreted a lipase protein AmLip with antimalarial activity. Further Western Blot analysis results showed that most of the secreted AmLip protein was bound to the surface of OMVs to form an OMV-AmLip complex with antimalarial activity ( Fig.13 Upper left). Immunoelectron microscopy confirmed the binding of AmLip to OMVs ( Fig.13 above right).

[0201] Further antimalarial activity detection experiments showed that OMV acquired antimalarial activity after AmLip binding ( Fig.13The Su_YN1 strain was obtained by knocking out AmLip using conventional methods. OMVs were prepared using the strain. Analysis showed that the OMVs had no antimalarial activity. The OMVs were incubated with purified AmLip protein. The OMVs could bind to the purified AmLip protein and obtain antimalarial activity ( Fig.13 These results suggest that OMVs may act as carriers to transport AmLip into Plasmodium to exert antimalarial effects.

[0202] To verify whether Su_YN1 OMVs really mediate the cross-kingdom delivery of AmLip into Plasmodium, the inventors incubated purified OMVs with RBCs infected with Plasmodium falciparum Pf3D7 and detected the distribution of OMVs (DiI staining) and AmLip proteins by indirect immunofluorescence. It was found that OMVs and AmLip were well co-localized and enriched in RBCs infected with Plasmodium ( Fig.14 Left). After OMV treatment, the cell membrane of Plasmodium-infected cells ruptured and the Plasmodium was lysed, and this effect was dependent on the loading of AmLip protein ( Fig.14 right).

[0203] In order to study the selectivity of OMVs entering Plasmodium, the inventors compared the ability of OMVs from different sources to enter Plasmodium. The results showed that only OMVs produced by Su_YN1 under serum induction conditions had the ability to efficiently enter Plasmodium ( Fig.15 top left).

[0204] Further studies have shown that the PC uptake pathway of malarial parasites mediates OMV endocytosis. Inhibition of the PC uptake pathway of malarial parasites by low temperature and sodium azide treatment significantly inhibited the entry of OMV into malarial parasites ( Fig.15 above right).

[0205] The above results indicate that the OMVs produced by serum-induced Su_YN1 are rich in serum-derived lipid components such as PC, and can efficiently deliver the antimalarial active protein AmLip into the malarial parasite through the malarial parasite PC uptake pathway.

[0206] This example shows that the OMV prepared by the present invention has the ability to efficiently target and enter eukaryotic cells such as Plasmodium. Live cell imaging experiments show that this new OMV can quickly enter Plasmodium ( Fig.15 It can be used as a new type of delivery tool to mediate the entry of exogenous substances into eukaryotic cells.

[0207] Example 12: Preparation of OMV vesicles with low LPS content and low toxicity using the serum induction technology of the present invention

[0208] By comparing the properties of OMVs produced by the W3110 strain and the Su_YN1 strain, the inventors found that the endotoxin LPS content of the Su_YN1 OMVs prepared by the serum induction method of the present invention was significantly reduced compared with the traditional method ( Fig.16 ), the LPS amount calculated by the Kdo method was less than 0.5 μg / 100 μg OMV, indicating that serum induction technology can be used to prepare OMV vesicle particles with low LPS content.

[0209] Since LPS is the main allergen and toxin of bacterial OMV, the inventors speculated that Su_YN1OMV prepared by serum induction technology may have lower in vivo toxicity and better in vivo tolerance. By injecting different doses of W3110OMV and Su_YN1 OMV prepared by serum induction technology into the tail vein, the inventors observed that mice died quickly after injection of 100μg W3110 OMV, while mice injected with up to 300μg Su_YN1 OMV prepared by serum induction technology were in good condition and survived completely. The survival rate at injection doses of 100μg and 300μg was 100% ( Fig.17 Left). Serum samples were collected 24 hours after OMV injection to detect TNFα, and it was found that W3110 OMV significantly activated serum TNFα, while the serum TNFα of Su_YN1 OMV prepared by serum induction technology did not change significantly ( Fig.17 Right), indicating that Su_YN1 OMV has good in vivo tolerance and safety.

[0210] In order to further confirm the in vivo safety of Su_YN1 OMV prepared by serum induction technology, the inventors took the liver and kidney of mice at the early (2 hours) and mid-late (16 hours) of OMV injection for morphological and pathological analysis. It can be seen that significant lesions occurred in the liver and kidney of mice injected with W3110 OMV, while there were no significant lesions in the liver and kidney of mice injected with Su_YN1 OMV prepared by serum induction technology ( Fig.18 ), indicating that the Su_YN1 OMV prepared by serum induction technology has no obvious toxicity in vivo. The present invention can obtain low-toxic and safe OMV vesicle materials by reducing the LPS content in the preparation of OMV.

[0211] Example 13: Preparation of low-toxic OMVs using serum-induced technology for rapid loading of primaquine for targeted treatment of liver-stage Plasmodium infection

[0212] The strain provided by the present invention can be used to add drugs that need to be loaded into OMVs during the bacterial induction of OMV culture, so that these drugs are carried into the OMVs as they are produced, and OMV particle precursors loaded with drugs are quickly prepared. This method is applicable to drugs that are not affected by bacteria and have no effect on bacterial growth and the production of OMVs.

[0213] In this embodiment, an application example of using OMV to load primaquine (PQ) for targeted treatment of hepatic stage malarial parasite infection is provided. Primaquine is the only antimalarial drug currently approved for clinical use to treat hepatic stage malarial parasites and their dormant larvae. It requires large doses and long-term medication, and can be used in combination with other antimalarial drugs to completely eliminate malarial parasite infection. PQ distribution in the circulatory system can cause a certain probability of acute hemolysis in patients with erythrocyte glucose-6-phosphate dehydrogenase (G6PD) deficiency. Therefore, an important direction of PQ for the treatment of hepatic stage malarial parasites is to reduce its plasma exposure time and quickly enrich in the liver.

[0214] First, the distribution of Su_YN1 OMVs prepared by serum induction technology in mice was analyzed. After DiI fluorescent labeling of OMVs, mice were injected into the tail vein, and the organs of mice were dissected. The distribution of fluorescence in the body was observed by imaging and frozen sections. It was found that serum-induced Su_YN1 OMVs were mainly distributed in the liver ( Fig.19 ).

[0215] The inventors used serum induction to prepare low-toxic Su_YN1 OMV loaded with PQ. On the one hand, OMV was used to target the liver to deliver drugs to the liver to eliminate liver-stage Plasmodium infection, and on the other hand, the distribution of PQ in the blood circulation system was reduced to avoid toxic side effects. First, by adding PQ to the serum-induced Su_YN1 culture system, the efficiency of PQ integration into OMV was tested. The results showed that PQ can be effectively integrated into OMV during the OMV formation process ( Fig. 20 HPLC-mass spectrometry results showed that after PQ bound to OMV, the molecular structure did not change ( Fig.21 ).

[0216] Next, OMV-PQ was used to conduct a treatment experiment for liver stage infection of Plasmodium berghei (PQ). After establishing liver infection in mice, a single injection of OMV-PQ and an equivalent dose of free PQ was used to track the infection status of Plasmodium berghei (PQ). Fig. 22 ). By quantifying the content of OMV combined with PQ, 100μg OMV / mice (containing 10μg PQ) were injected for treatment. The results showed that the injection of blank OMV or free PQ drugs could not inhibit the infection of Plasmodium, and the parasitemia rate of mice gradually increased after infection and died. The injection of OMV-PQ could prevent or eliminate Plasmodium infection in the liver of mice. The mice survived well, and the proportion of parasitemia was basically 0% ( Fig. 22 Down).

[0217] These results suggest that serum-induced preparation of low-toxic Su_YN1 OMV loaded with PQ can be used to develop targeted drugs to treat liver-stage Plasmodium. In addition, OMV loaded with other drugs can be used to treat other diseases.

[0218] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.

Claims

1. A method for preparing outer membrane vesicles (OMV), comprising the following steps: (i) culturing intestinal bacteria derived from blood-sucking insects in a culture medium so that the bacteria release vesicles into the culture medium; and (ii) collecting the vesicles in the culture medium.

2. The preparation method according to claim 1, characterized in that The preparation method includes the step of inducing with a serum-containing substance; preferably, the serum-containing substance includes: serum, plasma, serum extract or serum substitute; preferably, the serum-containing substance is derived from mice, rats, humans, cattle, pigs, rabbits, sheep, and horses.

3. The preparation method according to claim 1, characterized in that: The intestinal bacteria derived from the blood-sucking insects include intestinal bacteria derived from Anopheles or Aedes; preferably, the intestinal bacteria include Serratia; preferably, the intestinal bacteria include: Serratia ureilytica, Serratia marcescens, Serratia rubidaea, Serratia liquefaciens, Serratia plymuthica, Serratia ficaria, Serratia grimesii, Serratia fonticola, etc.; more preferably, the intestinal bacteria is Su_YN1, which is a strain with a preservation number of CGMCC No.18971.

4. The preparation method according to any one of claims 1 to 3, characterized in that: The preparation method comprises one or more of the following AG: A. The culture temperature of the culture medium for culturing bacteria in step (i) is 15 to 33° C., preferably 18 to 32° C., more preferably 20 to 30° C.; B. The bacterial inoculation ratio in step (i) is seed solution: culture solution = 1:100, wherein the bacterial OD value of the seed solution is 1.0 OD to 3.0 OD, preferably 2.0 OD to 3.0 OD; C. The culturing time of the bacteria in the culture medium in step (i) is 10 to 80 hours, preferably 12 to 60 hours, and more preferably 15 to 48 hours; D. The concentration of the serum is 3-20%, preferably 5-15%, more preferably 8-12%; E. The method for collecting vesicles is to collect vesicles by filtration, centrifugation, or salting out; preferably, the filtration is performed using a filter, and / or the centrifugation is performed at 4°C low temperature; more preferably, the filtration is performed using a 0.2 μm filter; and / or the centrifugation is performed by ultracentrifugation with a centrifugal force of 10000g-25000g, and most preferably, the centrifugal force is 15000g.

5. The preparation method according to any one of claims 1 to 3, characterized in that: The preparation method does not include a pre-concentration step, preferably does not include a step of using ultrafiltration concentration or detergent precipitation concentration, and more preferably the detergent is trichloroacetic acid (TCA); And / or, the preparation method does not require dialysis or gradient purification; And / or, the preparation method further comprises the step of detecting and / or identifying lipid components by lipidome cluster analysis; And / or, the preparation method further comprises a quantitative step, preferably the quantitative step is a quantitative detection by a BCA quantitative method based on total protein, and / or a Kdo quantitative method based on LPS content, and / or a quantitative method based on total lipid content; And / or, the preparation method further comprises the step of performing intuitive particle analysis using an NTA particle analyzer.

6. An isolated outer membrane vesicle (OMV), characterized in that The invention is prepared by the preparation method according to any one of claims 1 to 5.

7. The isolated outer membrane vesicle (OMV) according to claim 6, characterized in that The outer membrane vesicle has a feature selected from the group consisting of: The particles are uniform, with an average particle size of 100-150nm; A lipid composition having eukaryotic properties; preferably, the lipids include: phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, glycerophospholipids; preferably, the lipids are not mainly glycerophospholipids and LPS lipopolysaccharides; Has a protein composition derived from serum and blood-sucking insect-derived enteric bacteria; It has a low LPS to lipopolysaccharide ratio; preferably, the LPS amount is less than 0.5 μg / 100 μg OMV according to the Kdo method; more preferably, the LPS amount is less than 0.4 μg / 100 μg OMV according to the Kdo method.

8. A composition comprising the outer membrane vesicles according to claim 6 or 7; preferably, the composition does not contain any live bacteria and / or intact bacteria.

9. A pharmaceutical composition comprising: The isolated outer membrane vesicle (OMV) of claim 6 or 7; a therapeutic agent and / or a diagnostic agent integrated into or loaded into the outer membrane vesicle; and Pharmaceutically acceptable carrier or excipient.

10. The pharmaceutical composition according to claim 9, characterized in that The therapeutic agents include: anti-tumor drugs, anti-infective agents, anti-allergic agents, antianemic drugs, angiogenesis inhibitors, beta-adrenergic blockers, calcium channel antagonists, antihypertensive drugs, antidepressants, anticonvulsants, antibacterial drugs, antifungal drugs, antiviral drugs, antirheumatic drugs, antiparasitic drugs, antimalarial drugs, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, antidiabetic drugs, antiepileptic drugs, antihemorrhagic drugs, antihyperosmotic drugs, antiglaucoma drugs, immunomodulatory cytokines, sedatives, chemokines, vitamins, toxins, anesthetics, imaging agents and combinations thereof; Preferably, the therapeutic agent is an antimalarial drug for treating hepatic stage Plasmodium and its hypnozoites, in particular an antimalarial drug for treating parasitemia of hepatic stage Plasmodium and its hypnozoites; More preferably, the antimalarial drugs include artemisinin antimalarial drugs and aminoquinoline antimalarial drugs; Most preferably, the artemisinin antimalarial drug includes artemisinin, artesunate, artemether, dihydroartemisinin or arteether, and the aminoquinoline antimalarial drug includes chloroquine, chloroquine phosphate, piperaquine, primaquine or primaquine phosphate; preferably, the antimalarial drug is primaquine; and / or, The diagnostic agent includes: an imaging agent, an immunomodulator, an antigen, an adjuvant, a cytokine, a chemokine, an anticancer agent, an anti-infective agent, a nucleic acid, an antibody or a fragment thereof, and a fusion protein; preferably, the diagnostic agent is an agent for diagnosing malaria associated with hepatic stage Plasmodium and its hypnozoites; more preferably, the diagnostic agent is an agent for diagnosing parasitemia associated with hepatic stage Plasmodium and its hypnozoites.

11. A composite, characterized in that The complex comprises the isolated outer membrane vesicle (OMV) of claim 6 or 7 and a lipolytic enzyme; Preferably, the lipolytic enzyme is AmLip, or fragments, derivatives and analogs thereof, More preferably, the AmLip comprises a protein having an amino acid sequence as shown in SEQ ID NO: 2; or a derivative protein having an amino acid sequence having more than 90% sequence identity with SEQ ID NO: 2 and having the function of the protein shown in SEQ ID NO:

2.

12. Use of the isolated outer membrane vesicle (OMV) according to claim 6 or 7, the composition according to claim 8, the pharmaceutical composition according to claim 9 or 10, or the complex according to claim 11 in the preparation of a drug for preventing or treating a disease; preferably, the drug for preventing a disease is a vaccine; Preferably, the diseases include tumors, infections, allergies, anemia, hypertension, depression, convulsions, bacterial infections, fungal infections, viral infections, rheumatism, parasites, malaria, immune system diseases, nervous system diseases, diabetes, epilepsy, hemorrhage, hyperosmosis, glaucoma, sedation, toxins, and anesthesia; More preferably, the disease is malaria, in particular malaria associated with Plasmodium and its hypnozoites; Most preferred is malaria associated with hepatic stage Plasmodium and its hypnozoites, in particular parasitemia associated with hepatic stage Plasmodium and its hypnozoites.

13. Use of the outer membrane vesicle according to claim 6 or 7, the composition according to claim 8 or the complex according to claim 11 in the preparation of a product for loading and / or delivering drugs for preventing or treating diseases; preferably, the product is a vaccine; Preferably, the diseases include tumors, infections, allergies, anemia, hypertension, depression, convulsions, bacterial infections, fungal infections, viral infections, rheumatism, parasites, malaria, immune system diseases, nervous system diseases, diabetes, epilepsy, hemorrhage, hyperosmosis, glaucoma, sedation, toxins, and anesthesia; More preferably, the disease is malaria, in particular malaria associated with Plasmodium and its hypnozoites; Most preferred is malaria associated with hepatic stage Plasmodium and its hypnozoites, in particular parasitemia associated with hepatic stage Plasmodium and its hypnozoites.

14. The use according to claim 12 or 13, characterized in that The malarial parasites are malarial parasites that use insects, rodents, primates, poultry or birds as hosts that are susceptible to malarial parasites; preferably include: Plasmodium falciparum, Plasmodium berghei, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, Plasmodium brasilianum, Plasmodium cynomolgi, Plasmodium knowlesi, Plasmodium schwetzi, Plasmodium simium, Plasmodium chabaudi, Plasmodium yoelii, Plasmodium gallinulae, Plasmodium spp. gallinaceum), Plasmodium relictum; Preferably, the malarial parasite is a malarial parasite that uses malarial parasite-susceptible mosquitoes as hosts; more preferably, the malarial parasite-susceptible mosquitoes include: Anopheles gambiae and Aedes gambiae.

15. A method for inhibiting malarial parasites, comprising: The isolated outer membrane vesicles (OMV) of claim 6 or 7, the composition of claim 8 or the complex of claim 11 are used to deliver a drug that inhibits Plasmodium, or the pharmaceutical composition of claim 9 or 10 is used for inhibition.

16. A kit / medicine box for inhibiting Plasmodium or preventing and treating diseases related to Plasmodium infection, comprising: the isolated outer membrane vesicles according to claim 6 or 7; the composition according to claim 8; the pharmaceutical composition according to claim 9 or 10; or the complex according to claim 11, or a combination thereof.

17. Use of an intestinal bacterium derived from a blood-sucking insect or a culture thereof for preparing outer membrane vesicles (OMV); preferably, the intestinal bacterium derived from a blood-sucking insect comprises intestinal bacteria derived from Anopheles or Aedes; preferably, the intestinal bacteria comprises Serratia; preferably, the intestinal bacteria comprises: Serratia ureilytica, Serratia marcescens, Serratia rubidaea, Serratia liquefaciens, Serratia plymuthica, Serratia ficaria, Serratia grimesii, Serratia fonticola, etc.; more preferably, the intestinal bacteria is Su_YN1, which is a strain with a preservation number of CGMCC No.18971.

Citation Information

Patent Citations

  • Novel anti-malaria serratia and application thereof in blocking malaria transmission

    CN114306391A

  • Serratia marcescens lipase with effect of killing plasmodium and coding gene of serratia marcescens lipase

    CN114381445A